← brief for 2026-10-23 · Slowing decline

Finerenone-Empagliflozin Combination Therapy in Apparent Resistant Hypertension: A CONFIDENCE Trial Post Hoc Analysis.

Article B Peer reviewed Small trial

Key takeaways

This analysis looked at a trial of two drugs, finerenone and empagliflozin. The trial focused on people with kidney disease and type 2 diabetes. It checked if the drugs helped lower blood pressure in people with hard-to-control high blood pressure. The study was a post hoc analysis of a randomized trial. It did not report the exact number of people in this specific subgroup.

Who did this work

Agarwal R · Navaneethan SD · Correa-Rotter R · Estrella MM · Heerspink HJL · McGill JB · Mottl AK · Nangaku M · Rosenstock J · Rossing P · Vaduganathan M · Morales J

Source

Article · PubMed, CKD nutrition RCTs · 2026 Oct 23
https://pubmed.ncbi.nlm.nih.gov/42914747/